The global hypercalcemia treatment market is predicted to attain a valuation of USD 18.07 billion by the end of the year 2023. Over the forecast years, it is expected to expand at a CAGR rate of 11.8%. By following this significant growth rate, the overall market could reach a valuation of USD 55.07 billion by the year 2033.
Hypercalcemia Treatment Market Trend Analysis
Market Outlook
| Attributes | Market Insights |
|---|---|
| Market Value 2022 | USD 16.24 billion |
| Market Value 2023 | USD 18.07 billion |
| Market Value 2033 | USD 55.07 billion |
| CAGR 2023 to 2033 | 11.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for the hypercalcemia treatment was nearly USD 25.3 billion which is 57.8% of the global endocrinology drugs market in 2022. According to a global market survey, overall demand for hypercalcemia treatment services, in terms of value was around USD 9.64 billion in 2018.
There has been a stagnated rise across product segments of this market from 2018 and 2022. Further, the lockdown due to COVID-19 caused supply chain disruptions and discontinued business operations. As many biopharma companies had to wait for the availability of new batches of raw material for hypercalcemia drug production, the hypercalcemia treatment facilities also reduced their service offerings.
| Attributes | Details |
|---|---|
| Hypercalcemia Treatment Market Size (2018) | USD 9.64 billion |
| Market Size (2022) | USD 16.24 billion |
| Market (CAGR 2018 to 2022) | 11% |
The availability of advantageous reimbursement scenarios that allow patients to reduce treatment costs despite low-income eligibility continues to have an impact on the overall market. According to an article about hyperparathyroidism in the endocrinology magazine Medscape, roughly 66 women per 100,000 and 25 males per 100,000 suffer from primary hyperparathyroidism worldwide. Appropriate government policies as well as health insurance markets are expected to boost the market further through 2033.
A deteriorating lifestyle followed by increasing sending capacity has also boosted the market opportunities in emerging nations. Expanding medical tourism in certain emerging nations is also figured to influence the shift in hypercalcemia treatment hubs over the forecast years.
Improving product portfolios to increase patient compliance and simplicity of treatment has created new opportunities for market players in the last few years. Moreover, adopting new marketing tactics has aided the firms in expanding their regional footprint and product offerings setting up a promising market for the coming days. Also, expanding distribution networks in a limited competition scenario is creating favorable opportunities for drug manufacturers to establish their brand name.
Industry-led product portfolio diversification and regular product launches by key players have also encouraged the emergence of regional market players in recent years. Moreover, favorable government policies for start-up companies & government funding have also strengthened the market position of new players.
Principal Consultant
In recent years, hypercalcemia drug manufacturers have been investing heavily in research studies to create alternative pharmacological treatments for surgeries. However, once a hypercalcemia drug is developed, the long process of adoption among customers poses a significant challenge for the market players.
Proper distribution of hypercalcemia medicines faces logistical challenges as well in terms of manufacturers locating appropriate channels. Independent pharmacies and drug stores avoid stocking such drugs due to high prices and low demand in local markets. Moreover, logistical arrangements also vary from country to country limiting the cost recovery from small patient pools in a specific region.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 45.7% |
| Europe | 26.7% |
In 2022, the United States accounted for more than 86.8% of North America's total demand for hypercalcemia treatment, in terms of value. Research and development activities concentrating on the development of pharmaceuticals used in hypercalcemia therapy are in growing demand in the United States. Besides the presence of leading players, enhanced healthcare infrastructure might positively affect the growth of this regional market over the projected period.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 39.7% |
| Germany | 6.6% |
| Japan | 9.9% |
As per our estimates, Germany is predicted to account for roughly 6.6% of the market by the end of 2033. The higher demand for hypercalcemia therapy in Germany is mostly due to the prevalence of hypercalcemia linked with malignancies among the citizens. Taking a step further, advantageous reimbursement scenarios and great patient knowledge of hypercalcemia represent a promising growth rate for the region.
The United Kingdom is projected to witness a high growth rate in demand for hypercalcemia treatment within Europe. A strong base of medical tourism in the country is expected to drive the adoption of such healthcare services at a high rate. Furthermore, favorable regulatory situations are projected to provide new chances in the United Kingdom hypercalcemia treatment market through 2033.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 10.2% |
| China | 13.3% |
| India | 11.8% |
| Australia | 8.7% |
The demand for hypercalcemia treatment is expected to develop at a CAGR of roughly 13.3% in China from 2023 to 2033. Growing economies, continuous expansion of the healthcare industry in China, and great access to healthcare are some of the primary drivers of the China market.
India is likely to closely follow China in sales of Hypercalcemia drugs as well as the adoption of treatment services owing to its huge population base in the country. Regulatory reforms, favorable government policies, and improved healthcare infrastructure are expected to have a positive impact on present and future market trends as well.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attributes | Details |
|---|---|
| Top Product Type | Bisphosphonates |
| Market Share in 2022 | 70.1% |
In terms of drug type, bisphosphonates held the maximum share of 70.1% in 2022, expanding by 11.6% CAGR during the historical period 2018 to 2022. Bisphosphonates are utilized as the first line of treatment for hypercalcemia. So their demand is expected to remain intact during the forecast period followed by the growing prevalence of malignancies.
| Attributes | Details |
|---|---|
| Top Distribution Channel Type | Hospitals |
| Market Share in 2022 | 38.5% |
The hospitals accounted for 38.5% of the sales of hypercalcemia treatment drugs and services in 2022 making it the leading distribution channel for the global market. The rising number of cancer patients who opt for treatment at hospitals by hypercalcemia specialists is the leading cause of hospitals contributing to the significant market share in the market.
Companies indulged in developing hypercalcemia drugs and treatment therapies are actively seeking to strengthen their position through approval, and agreements with established healthcare institutes. Also, collaborations, mergers & acquisition partnerships with regional players can accelerate their strategy to capture a significant share of the emerging markets.
The emergence of many biotech firms for conducting research and development on hypercalcemia diagnosis and therapy also could be a factor for further market growth. They are developing medicines and APIs manufactured in individual and combination doses for the treatment of hypercalcemia associated with thyroid tumors and other illnesses.
Key Developments
| Attributes | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | USD billion for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and The Middle East & Africa (MEA) |
| Key Countries Covered | The United States, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Northern Africa, and South Africa |
| Key Market Segments Covered | Product, Distribution Channel, and Region |
| Key Companies Profiled | Amgen Inc.; Pfizer Inc.; Mylan N. V.; Sunovion; Procter And Gamble; Apotex Corporation; Genentech, Inc.; Novartis AG; Bayer AG; Hoffmann La Roche; Atnahs Pharma; Cipla Inc.; Sun Pharmaceuticals Industries Ltd; Dr. Reddy’s Laboratories; Aurobindo Pharma Limited |
| Pricing | Available upon Request |
The hypercalcemia treatment market is estimated to secure a valuation of USD 18.07 billion in 2023.
Top-performing 6 countries held roughly 65.3% of the global market in 2022.
The global adoption of hypercalcemia treatment services is expected to surge at 11.8% CAGR through 2033.
The United States leads the market with a global share of 39.7% in 2022.
Amgen, Pfizer, and Mylan are some of the leading hypercalcemia treatment providers.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Bisphosphonates 5.1.1. Clodronate 5.1.2. Etidronate 5.1.3. Ibandronate 5.1.4. Pamidronate 5.1.5. Zoledronic Acid 5.2. Calcitonin 5.3. Glucocorticoids 5.4. Denosumab 5.5. Calcimimetics 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Hospitals 6.2. Clinics 6.3. Independent Pharmacy & Drug Stores 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Amgen Inc 17.2. Pfizer Inc. 17.3. Mylan N. V. 17.4. Sunovion 17.5. Procter And Gamble 17.6. Apotex Corporation 17.7. Genentech, Inc. 17.8. Novartis AG 17.9. Bayer AG 17.10. Hoffmann La Roche 17.11. Atnahs Pharma 17.12. Cipla Inc. 17.13. Sun Pharmaceuticals Industries Ltd 17.14. Dr. Reddy’s Laboratories 17.15. Aurobindo Pharma Limited 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Hypercalcemia Treatment Market
